Clinical Trials
16 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05919264 2026-05-28
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT04281381 2026-05-15
Observing People With Desmoid-Type Fibromatosis
Memorial Sloan Kettering Cancer Center
Recruiting
NCT06268457 2026-05-14
Embodesmo
Istituto Ortopedico Rizzoli
Recruiting
NCT06660121 2026-05-14
ECT-DESMO
Istituto Ortopedico Rizzoli
Withdrawn
NCT06224283 2026-05-12
Cryomics
Istituto Ortopedico Rizzoli
Recruiting
NCT05041036 2026-05-08
Individual Patient Compassionate Use of Nirogacestat
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Available
NCT07170644 2026-05-08
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2 Active not recruiting
NCT07176689 2026-05-08
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 4 Recruiting
NCT02402244 2026-05-05
Project: Every Child for Younger Patients With Cancer
Children's Oncology Group
Recruiting
NCT04851119 2026-05-05
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT07541430 2026-04-30
A Study in Adults With Desmoid Tumors
Elpiscience Biopharma, Ltd.
Phase 2 Recruiting
NCT06502483 2026-04-21
PRISM
Dana-Farber Cancer Institute
Phase NA Completed
NCT04195399 2026-04-15
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Children's Oncology Group
Phase 2 Active not recruiting
NCT02867033 2026-03-30
ALTITUDES
Centre Oscar Lambret
Phase NA Active not recruiting
NCT07496242 2026-03-27
Immunological Phenotype of Desmoid-fibromatosis-affected Patients.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting